☆ 4.6 Article

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Maura L. Gillison et al.

Summary: Nivolumab has shown significant improvement in overall survival for patients with squamous cell carcinoma of the head and neck, particularly those who have failed platinum-based therapy. Long-term follow-up analysis confirms the sustained efficacy of nivolumab as a first-line treatment, with no new safety concerns identified.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma

Tomofumi Naruse et al.

Summary: The study suggests that the weekly cetuximab plus paclitaxel regimen may be a treatment option for patients with recurrent or metastatic oral squamous cell carcinoma that is refractory to platinum-based chemotherapy or progressive disease after chemotherapy. Adverse events were tolerable and manageable, with overall efficacy being relatively promising.

ANTICANCER RESEARCH (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Joel Guigay et al.

Summary: The aim of this study was to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen in patients with recurrent or metastatic HNSCC. The results showed no significant difference in overall survival between the two regimens, but the TPEx regimen had a more favorable safety profile.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study

Ifigenia Vasiliadou et al.

Summary: Nivolumab shows promising efficacy and good tolerability in recurrent/metastatic head and neck squamous cell carcinoma, with real-world outcomes comparable to clinical trials. Treatment with nivolumab may be more effective in patients who develop immune-related toxicities.

CANCERS (2021)

Add to Collection

Article Oncology

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

Michael Pogorzelski et al.

Summary: A retrospective analysis of 218 r/m SCCHN patients treated with cetuximab-based chemoimmunotherapy revealed that ECOG performance status, age, anemia, and neutrophil-to-lymphocyte ratio were independently associated with inferior overall survival. A prognostic clinical score was established to stratify patients into different risk subgroups. Patients with low risk scores showed better outcomes under first-line cetuximab-based therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Otorhinolaryngology

Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany

Prianka Singh et al.

Summary: The study showed that nivolumab has survival benefits for patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck in a real-world setting. Factors such as ECOG performance status, platinum sensitivity, and older age were associated with longer overall survival, while the number of prior lines of therapy had no significant effect.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2021)

Add to Collection

Review Oncology

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

Agustin Falco et al.

Summary: Cisplatin is the standard treatment for squamous cell carcinoma of the head and neck, but its toxicities can significantly impact patients' quality of life. The decision to administer cisplatin depends on various patient factors, and careful evaluation is required by healthcare providers.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Review Oncology

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy

Sandro V. Porceddu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes

Jong Chul Park et al.

ORAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J-P Machiels et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

1138PFirst-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

C Even et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

Add to Collection

Article Oncology

Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan

Daisuke Sano et al.

ANTICANCER RESEARCH (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

Add to Collection

Article Oncology

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

Tomohiro Enokida et al.

FRONTIERS IN ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

R. Hitt et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Oncology

Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium

Mia Hashibe et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)

Add to Collection

Article Medicine, General & Internal

Platinum-based chemotherapy plus cetuximab in head and neck cancer

Jan B. Vermorken et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.